Right Patient, Right Treatment, Right Time: Utilizing Early, High-Efficacy Therapies to Improve Outcomes in RRMS

CMEO Webcast

Premiere Date: Monday, June 8, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other


Credit Expiration Date: Tuesday, June 8, 2021

Begin Activity Now

Faculty


Fred D. Lublin, MD, FAAN, FANA Fred D. Lublin, MD, FAAN, FANA 
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, NY

Joseph R. Berger, MD, FACP, FAAN, FANA Joseph R. Berger, MD, FACP, FAAN, FANA 
Professor of Neurology
Associate Chief, Multiple Sclerosis Division
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA

Anne H. Cross, MD Anne H. Cross, MD 
Professor of Neurology
Manny and Rosalyn Rosenthal and Dr. John L. Trotter Multiple Sclerosis
Center Chair in Neuroimmunology
Washington University School of Medicine
St. Louis, MO

Statement of Need

Recent studies have demonstrated the benefits of early and aggressive treatment strategies in reducing disability progression and the frequency of relapses in patients with relapsing remitting multiple sclerosis (RRMS), marking a paradigm shift in the treatment of patients with RRMS. The traditional escalation approach is now often set aside in favor of the more individualized "induction" approach, which utilizes "early and aggressive" treatment with high-efficacy disease-modifying therapies (DMTs) to treat patients with high-risk disease.

The induction approach requires selection of DMTs based on disease activity, prognostic factors, and patient characteristics. This is challenging for clinicians due to the expanding treatment landscape for RRMS and the lack of specific guidelines. Additionally, neurologists often lack the knowledge and competence to identify patients who are candidates for this approach.

In this CME Outfitters virtual symposium, expert faculty will focus on the prognostic factors that should be considered when developing treatment plans for patients with MS, as well as the latest clinical data on approved and emerging DMTs, so that clinicians can confidently develop tailored treatment approaches based on individual patient characteristics and appropriately monitor treatment response, safety, and tolerability.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Select patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
  • Develop tailored treatment approaches based on individual patient characteristics.
  • Apply the latest clinical data on approved and emerging DMTs in monitoring treatment response, safety, and tolerability.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Describe patients with RRMS who are likely to benefit from early treatment with high-efficacy DMTs.
  • Summarize a tailored treatment approach based on individual patient characteristics.
  • Explain the latest clinical data on approved and emerging DMTs in monitoring treatment response, safety, and tolerability.

Financial Support

Supported by educational grants from Celgene Corporation, a Bristol Myers Squibb company and from Genentech, a member of the Roche Group.

Target Audience

Neurologists, MS specialists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hour (0.15 CEUs). Universal Activity Number:
Enduring: 0376-0000-20-093-H01-P

Type: knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Format:
Enduring material

ABPN MOC Credit:
ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Note to PAs: PAs may claim a maximum of 1.5 Category 1 Credits for completing this activity. NCCPA accepts A AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education or a recognized state medical society.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr.Lublin reports that he receives research support from Actelion Pharmaceuticals; Biogen; Brainstorm Cell Therapeutics Inc; National Institutes of Health (NIH); National Multiple Sclerosis Society (NMSS); Novartis; and Sanofi. He has consulting agreements, serves on advisory boards, or Data and Safety Monitoring Board for Acorda Therapeutics; Actelion Pharmaceuticals/Janssen Pharmaceuticals, Inc.; Apitope; Brainstorm Cell Therapeutics Inc.; Atara Biotherapeutics, Inc.;Avotres; Biogen; EMD Serono, Inc; GW Pharmaceuticals; Immunic, Inc.; Innate Immunotherapeutics; Jazz Pharmaceuticals, Inc.; Mapi Pharma; MedDay Pharmaceuticals; MedImmune/ Viela Bio; Mylan; Novartis; Orion Biotechnology; Polpharma; Receptos, Inc./Celgene Corporation; Roche/Genentech, Inc.; Sanofi/Genzyme Corporation; Teva Pharmaceuticals; The Population Council, Inc. and TG Therapeutics. He is a speaker for Sanofi (non-promotional).

Dr. Berger reports he received research support from Biogen and Genentech, Inc. He serves on the advisory committee for Excision BioTherapeutics; Inhibikase Therapeutics, Inc.; and Novartis. He serves as a consultant for Amgen Inc.; Biogen; Celgene Corporation; Dr. Reddy's Laboratories; Encycle Therapeutics; Genentech, Inc./Roche; Mapi-Pharma; Merck & Co., Inc.; Morphic Therapeutic; Novartis; EMD Serono, Inc.; and Shire.

Dr. Cross reports she receives research support from The Conrad N. Hilton Foundation and U.S. Department of Defense. She serves on the advisory committee for EMD Serono, Inc. and Genentech, Inc./Roche. She is consultant for Biogen; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc./Roche; and Novartis.

Alaeddin Abukabda, MS, DMD, PhD (planning committee) has no disclosures to report.

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MMV-105-060820-90